Author: Ravi Shankar

DENVER, Nov. 13, 2026 (GLOBE NEWSWIRE) — ArrowMark Financial Corp. (Nasdaq: BANX) (“ArrowMark Financial” or the “Company”), an SEC registered closed-end management investment company, today announced that its Board of Directors has declared a monthly cash distribution of $0.15 per share for November 2026. The total distribution of $0.15 per share will be payable on November 30, 2026, to shareholders of record on November 23, 2026.

About ArrowMark Financial Corp.

ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market under the symbol “BANX.” Its investment objective is to provide shareholders with current income. The Fund pursues its objective by investing primarily in regulatory capital securities of financial institutions. ArrowMark Financial is managed by ArrowMark Asset Management, LLC. To learn more, visit ir.arrowmarkfinancialcorp.com or contact the Fund’s secondary market service agent at 877-855-3434.

Disclaimer and Risk Factors:

There is no assurance that ArrowMark Financial will achieve its investment objective. ArrowMark Financial is subject to numerous risks, including investment and market risks, management risk, income and interest rate risks, banking industry risks, preferred stock risk, convertible securities risk, debt securities risk, liquidity risk, valuation risk, leverage risk, non-diversification risk, credit and counterparty risks, market at a discount from net asset value risk and market disruption risk. Shares of closed-end investment companies may trade above (a premium) or below (a discount) their net asset value. Shares of ArrowMark Financial may not be appropriate for all investors. Investors should review and consider carefully ArrowMark Financial’s investment objective, risks, charges and expenses. Past performance does not guarantee future results.

The Annual Report, Semi-Annual Report and other regulatory filings of the Fund with the SEC are accessible on the SEC’s website at www.sec.gov and on the Fund’s website at ir.arrowmarkfinancialcorp.com.

Contact:

BANX@destracapital.com 

Destra Capital Advisors LLC (877) 855-3434
Destra Capital Advisors LLC provides secondary market services for the Fund by agreement.

VANCOUVER, British Columbia, Nov. 13, 2026 (GLOBE NEWSWIRE) — Refined Energy Corp. (CSE: RUU) (OTC: RRUUF) (FSE: CWA0) (“Refined” or the “Company”) is pleased to announce the appointment of Leo Power to its board of directors, effective November 13, 2026.

Mr. Power brings experience in the resource sector, corporate governance and government relations, including longstanding ties to Newfoundland and Labrador. He serves as a director of Q2 Metals Corp., Integral Metals Corp. and the St. John’s International Airport Authority and as a member of the Atlantic Canada Ambassadors Council for the Fraser Institute. Earlier in his career, he advised a senior federal Cabinet Minister and a former Premier of Newfoundland and Labrador.

Mr. Power co-founded the Newfoundland and Labrador chapter of the Institute of Corporate Directors. He holds an MBA through the joint Kellogg–Schulich program and a master’s degree in Oil and Gas Studies from Memorial University.

“We are pleased to welcome Leo to Refined’s board,” said Mark Fields, Chief Executive Officer. “His resource sector experience, governance background and connections in Newfoundland and Labrador will bring a valuable perspective as we advance Golden Goose and evaluate opportunities to strengthen our presence in the region.”

Equity Incentive Grants

The Company also announces that, effective November 13, 2026, it has granted an aggregate of 2,200,000 stock options (“Options”) and 2,200,000 restricted share rights (“RSRs”) to certain directors, officers and consultants of the Company pursuant to its equity incentive plan (the “Plan”). Each Option entitles the holder to acquire one common share at an exercise price of $0.20 until November 13, 2028. The Options and RSRs, and any common shares issued on the exercise of the Options or the settlement of the RSRs before March 14, 2027, are subject to a hold period expiring March 14, 2027, in accordance with the policies of the Canadian Securities Exchange (the “CSE”). The grants are subject to the terms of the Plan and the policies of the CSE.

About Refined Energy Corp.

Refined Energy Corp. is a Canadian mineral exploration company focused on the acquisition, exploration and development of strategic mineral projects in North America, including the Golden Goose gold-antimony project in Newfoundland and Labrador.

ON BEHALF OF THE BOARD OF DIRECTORS

Eli Dusenbury
Chief Financial Officer

For further information, please contact:
Refined Energy Corp.
Telephone: (604) 398-3378
Email: info@refinedenergy.com
Website: www.refinedenergy.com

Forward-Looking Information

This news release contains certain statements that constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information in this news release includes, but is not limited to, statements regarding the anticipated contribution of Mr. Power to the Company; the Company’s plans to advance the Golden Goose project; and the Company’s evaluation of opportunities to strengthen its presence in Newfoundland and Labrador. Forward-looking information is often, but not always, identified by words such as “anticipate”, “believe”, “expect”, “intend”, “plan”, “potential”, “will” and similar words and expressions. Such forward-looking information is based on management’s current expectations, estimates, projections, assumptions and beliefs, including assumptions regarding the availability of financing, personnel and other resources; the receipt and maintenance of required permits, approvals and authorizations; the Company’s ability to carry out its exploration and corporate plans as currently contemplated; and general business, economic and market conditions. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied, including risks relating to mineral exploration and development; the speculative nature of mineral exploration; the absence of defined mineral resources or reserves at the Golden Goose project; the availability and terms of financing; commodity prices; market and economic conditions; regulatory, permitting and environmental matters; operational and technical risks; the ability to attract and retain qualified personnel and consultants; and the other risks described in the Company’s public disclosure documents. Although the Company believes that the assumptions and expectations reflected in such forward-looking information are reasonable, there can be no assurance that they will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. The forward-looking information in this news release is provided as of the date hereof, and the Company disclaims any intention or obligation to update or revise such information, whether as a result of new information, future events or otherwise, except as required by applicable law. 

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

WILMINGTON, Mass., Nov. 13, 2026 (GLOBE NEWSWIRE) — Liberty Defense Holdings Ltd. (“Liberty” or the “Company”) (NASDAQ: DETX; TSXV: SCAN), a leading provider of AI-based next-generation detection solutions for concealed weapons and threats, issues this clarifying news release requested by the TSX Venture Exchange (the “TSXV”) regarding a credit facility and term loan entered into by the Company with PFF, LLC (“Parabilis”) previously announced on August 22, 2024.

The Company’s wholly-owned subsidiary Liberty Defense Technologies Inc. (the “Subsidiary”) and Parabilis entered into a Loan and Security Agreement dated August 19, 2024, as amended March 15, 2025, July 15, 2025, August 14, 2025 and September 1, 2025, pursuant to which Parabilis provided the Subsidiary with a US$1.8 million term loan (the “Term Loan”) and a US$2.5 million revolving credit facility (the “Credit Facility”) secured by substantially all of the Subsidiary’s assets, with the obligations of the Subsidiary unconditionally guaranteed by the Company. The Credit Facility and Term Loan were established to provide the Company with additional working capital flexibility.

The Credit Facility bears interest at 14.99% per annum and the Term Loan bears interest at 17.99% per annum payable monthly in arrears. The Term Loan had a term of 104 weeks and was scheduled to mature on August 15, 2026. The Credit Facility originally had a maturity date of August 31, 2025, with an option to extend at Parabilis’ sole discretion. On September 1, 2025, the parties amended the Credit Facility by extending the maturity date to May 31, 2026, with automatic one-year renewals unless Parabilis provides 90-days’ notice and the Company agreeing to pay a 0.083% monthly commitment fee. On August 14, 2025, the Term Loan was amended to provide for additional advances which contemplated total principal advances of approximately US$2.9 million, but only US$650,000 in additional advances were funded, resulting in total funded principal advances of US$2.45 million to the Subsidiary.

The borrowing base for the Credit Facility is determined based on the following percentages: 90% of eligible billed receivables, 65% of eligible unbilled receivables, and 30% of eligible delivery orders. The aggregate of eligible billed and unbilled receivables, along with eligible delivery orders, establishes the Subsidiary’s borrowing capacity under the Credit Facility. When invoicing occurs, payments on the invoices are applied directly to the outstanding principal and interest on the Credit Facility. As of the date of this press release US$Nil is outstanding under the Credit Facility and all principal and accrued interest under the Term Loan have been fully repaid and there is no outstanding balance under the Term Loan.

About Liberty Defense

Liberty Defense (NASDAQ: DETX; TSXV: SCAN) provides multi-technology security solutions for concealed weapons detection in high volume foot traffic areas and locations requiring enhanced security such as airports, stadiums, schools, and more. Liberty’s HEXWAVE product, for which the Company has secured an exclusive license from Massachusetts Institute of Technology (MIT), as well as a technology transfer agreement for patents related to active 3D radar imaging technology, provides discrete, modular, and scalable protection to provide layered, stand-off detection capability of metallic and non-metallic weapons. Liberty has also recently licensed the millimeter wave-based, High-Definition Advanced Imaging Technology (HD-AIT) body scanner and shoe scanner technologies as part of its technology portfolio. Liberty is committed to protecting communities and preserving peace of mind through superior security detection solutions.

For updates and news, please visit the Company website to subscribe to email alerts or follow Liberty Defense on social channels.

FORWARD-LOOKING STATEMENTS
When used in this press release, the words “estimate”, “project”, “belief”, “anticipate”, “intend”, “expect”, “plan”, “predict”, “may” or “should” and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements and information. Although Liberty believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in the forward-looking statements and information in this press release are reasonable, undue reliance should not be placed on them because Liberty can give no assurance that such statements will prove to be correct. Such statements and information reflect the current view of Liberty.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. There are a number of important factors that could cause Liberty’s actual results to differ materially from those indicated or implied by forward-looking statements and information, including those appearing in Liberty’s public filings. Such factors include, among others: currency fluctuations; limited business history of Liberty; disruptions or changes in the credit or security markets; results of operation activities and development of projects; project cost overruns or unanticipated costs and expenses; general development, market and industry conditions; and other factors described in Liberty’s public filings. Liberty undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of its securities or its respective financial or operating results (as applicable).

Liberty cautions that the foregoing list of material factors is not exhaustive. When relying on Liberty’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Liberty has assumed that the material factors referred to in the previous paragraph will not cause such forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors. The forward-looking information contained in this press release represents the expectations of Liberty as of the date of this press release and, accordingly, are subject to change after such date. Liberty does not undertake to update this information at any particular time except as required in accordance with applicable laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

CONTACT: Investor Relations:

For further information about Liberty Defense, please contact:

Kevin O’Dowd
Investor Relations
617-755-4602
kodowd@libertydefense.com

For sales information, please contact:

Ian McNaughton
Senior Director Business Development, Liberty Defense
613-292-3669
imcnaughton@libertydefense.com

GREENWICH, Conn., Nov. 13, 2026 (GLOBE NEWSWIRE) — Stardust Power Inc. (“Stardust Power” or the “Company”), an American developer of battery-grade lithium carbonate, today announced its financial results for the quarter ended September 30, 2026, and provided an update on its corporate developments and the development of its proposed lithium refinery project in Muskogee, Oklahoma.

Third Quarter 2026 Business Updates and Subsequent Events:

• Muskogee Lithium Refinery: The Company continued to test soil core samples taken from its Muskogee, Oklahoma site as part of the Company’s third-party geotechnical evaluation of site conditions. The proposed refinery project is designed for a nameplate capacity of up to 50,000 mtpa of battery grade lithium carbonate.
• Houston Office Expansion: In October 2026, Stardust Power announced the opening of a new office in Houston, Texas, to support project execution, engineering coordination and commercial activities associated with its proposed Muskogee lithium refinery. The Company’s Oklahoma City office remains operational.
• Conversion of Outstanding Principal Debt: During the third quarter and subsequent to quarter-end, the Company has no principal balance remaining under the previously disclosed convertible note after converting the outstanding principal into common stock, with approximately $53,000 in accrued default interest remaining payable.
• Nasdaq Delisting: Effective October 23, 2026, the Company’s common stock and public warrants were suspended from trading on Nasdaq for the failure to maintain a minimum trading price of $0.10 per share. Management continues to evaluate the Company’s strategic and capital markets alternatives and will provide further updates as appropriate.

Third Quarter 2026 Financial Highlights:

• As of September 30, 2026, the Company had cash of approximately $4.6 million, compared to $3.5 million as of December 31, 2025. The increase primarily reflects proceeds from equity financing activities, partially offset by cash used in operations and continued investment in the Muskogee lithium refinery project.
• For the three months ended September 30, 2026, the Company reported a net loss of $2.8 million, compared to $4.5 million for the corresponding period in 2025. The decrease primarily reflects lower general and administrative expenses and a favorable change in the fair value of warrant liabilities, partially offset by increased financing-related costs associated with the Company’s capital structure.
• Basic and diluted loss per share was $(0.15) for the third quarter of 2026, compared to $(0.53) in the prior-year period. The decrease reflects a lower net loss and a higher weighted average number of common shares outstanding following equity issuances.
• Net cash used in operating activities for the nine months ended September 30, 2026, was $6.3 million, compared to $6.5 million during the same period in 2025, reflecting continued investment in advancing the business while maintaining disciplined cash management.
• Net cash used in investing activities for the nine months ended September 30, 2026, was $0.3 million, compared to $3.0 million during the same period in 2025, primarily reflecting continued but more measured capital project expenditures related to the development of the Muskogee lithium refinery.
• Net cash provided by financing activities for the nine months ended September 30, 2026, was $7.7 million, compared to $10.2 million during the same period in 2025. Financing activities in 2026 primarily reflected proceeds from the Company’s equity financing facilities, while the prior-year period benefited from public offerings and warrant exercises.

About Stardust Power 

Stardust Power is building one of America’s largest battery-grade lithium carbonate refineries in Muskogee, Oklahoma, strategically located in the center of the United States’ growing energy and manufacturing corridor. The refinery is expected to have production capacity of up to 50,000 metric tons per annum and addresses the critical shortage of U.S. lithium refining capacity. Stardust Power is focused on building a resilient American battery supply chain.

For more information, visit www.stardust-power.com.

Stardust Power Contacts 

For Investors:

Johanna Gonzalez
investor.relations@stardust-power.com

For Media:

Michael Thompson
media@stardust-power.com

Cautionary Statement Regarding Forward-Looking Statements 

This press release and any oral statements made in connection herewith include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are any statements other than statements of historical fact, and include, but are not limited to, statements regarding the expectations, hopes, beliefs, intentions, plans, objectives, goals, prospects, financial results or strategies regarding us and the future held by our management team and the products and markets, future events, future financial condition, expected future revenues or performance, financing needs, our ability to continue as a going concern, business trends and market opportunities of our business, as well as statements regarding the expected capital expenditures, risks, production level, produced lithium quality, project design, feedstock supply, financing arrangements, final investment decision, development, construction, permits and related timelines with respect to the Company’s Muskogee lithium refinery. These forward-looking statements are based on management’s current beliefs and assumptions, based on currently available information, as to the outcome and timing of future events. Forward-looking statements may be identified by words such as “anticipate,” “appears,” “approximately,” “believe,” “continue,” “could,” “designed,” “effect,” “estimate,” “evaluate,” “expect,” “forecast,” “goal,” “initiative,” “intend,” “may,” “objective,” “outlook,“ ”plan,“ ”potential,“ ”priorities,“ ”project,“ ”pursue,“ ”seek,“ ”should,“ ”target,“ ”when,“ ”will,“ ”would,” or the negative of any of those words or similar expressions that predict or indicate future events or trends or that are not statements of historical fact, although not all forward-looking statements contain such identifying words. In making these statements, we rely upon beliefs, assumptions and analysis based on our experience and perception of historical trends, current conditions, and expected future developments, as well as other factors we consider appropriate under the circumstances. We believe these beliefs and judgments are reasonable, but these statements are not guarantees of any future events, financial results or outcomes, or the timing of such. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events, results, outcomes and circumstances, and the timing thereof, are difficult or impossible to predict and may differ from our beliefs, assumptions or predictions. Many actual events and circumstances are beyond our control.  

These forward-looking statements are subject to a number of risks and uncertainties, including the ability of Stardust Power to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of Stardust Power to grow and manage growth profitably, maintain key relationships and retain its management and key employees; risks related to the price of Stardust Power’s securities, including volatility resulting from recent sales of securities, issuance of debt, and exercise of warrants, changes in the competitive and highly regulated industries in which Stardust Power plans to operate, variations in performance across competitors, changes in laws and regulations affecting Stardust Power’s business and changes in the combined capital structure; the regulatory environment and our ability to obtain necessary permits and other governmental approvals for our operation; Stardust Power’s need for substantial additional financing to execute our business plan and our ability to access capital and the financial markets; worldwide growth in the adoption and use of lithium products; the Company’s ability to enter into and realize the anticipated benefits of offtake and license and other commercial agreements; risks related to the ability to implement business plans, forecasts, and other expectations and identify and realize additional opportunities; the substantial doubt regarding the Company’s ability to continue as a going concern and the need to raise capital in the near term in order to maintain the Company’s operations; our ability to remain in compliance with the covenants and other terms of our financing arrangements; our ability to raise additional capital; and those factors described or referenced in the Company’s filings with the SEC, including the Company’s Registration Statement on Form S-1 filed with the SEC on February 12, 2026 and Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 25, 2026. The foregoing list of factors is not exhaustive. If any of these risks materialize or our assumptions prove incorrect, actual results, outcomes, performance or achievements, or the timing of such results, outcomes, performance or achievements could differ materially from those expressed or implied by these forward-looking statements. There may be additional risks that we do not presently know or that we currently believe are immaterial that could also cause actual results, outcomes, performance or achievements, or the timing of such results, outcomes, performance or achievements to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect our expectations, plans or forecasts of future events and views as of the date of this press release. We anticipate that subsequent events and developments will cause our assessments to change. 

We caution readers not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update publicly or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other factors that affect the subject of these statements, except where we are expressly required to do so by law. All written and oral forward-looking statements attributable to us are expressly qualified in their entirety by this cautionary statement. 

CALGARY, Alberta, Nov. 13, 2026 (GLOBE NEWSWIRE) — Global Uranium Corp. (CSE: GURN | OTCQB: GURFF | FRA: Q3J0) (the “Company” or “Global Uranium”) announces its engagement of Nordcore Media LLC (address: 30 N Gould St, Suite R, Sheridan, Wyoming 82801; email: olga@nordcoremedia.net) (“Nordcore”) to provide digital marketing and investor awareness services designed to increase awareness of the Company and its uranium exploration portfolio.

Marketing activities are expected to commence on or about November 14, 2026, with an anticipated campaign duration of 60 to 90 days. The Agreement provides for an initial contractual term of four months or until the budget is fully spent, subject to earlier termination in accordance with its terms.

Under the Agreement, Nordcore is to develop and manage online advertising campaigns, including the preparation of advertorials, written content, text and display advertisements, and dedicated landing pages. Services also include keyword research, audience targeting, remarketing, campaign optimization and coordination with third-party advertising distributors. Marketing activities may be conducted through search engine advertising, including Google Ads, digital display advertising networks, social media platforms, financial news and investor-focused websites, and email newsletters (the “Services”).

The Company will pay $250,000 CAD in consideration for the Services, inclusive of advertising expenditures. No shares, stock options or other securities will be issued as compensation under the Agreement. Nordcore and its principals are at arm’s length to the Company and, to the Company’s knowledge, do not own, directly or indirectly, any securities of the Company.

About Global Uranium Corp.

Global Uranium Corp. is an exploration-stage company focused on uranium assets primarily in North America. Its portfolio includes the Wing Lake Property and an interest in the Astro Uranium Project in Saskatchewan, together with uranium projects in Wyoming’s Great Divide Basin, Gas Hills and Copper Mountain districts.

On behalf of the Board of Directors

Ungad Chadda
CEO and Director

For further information:
Telephone: 587-330-0045
Email: info@globaluranium.com
Website: www.globaluranium.com

Forward-Looking Information

This news release contains forward-looking information and forward-looking statements (collectively, “forward-looking information”) within the meaning of applicable Canadian securities legislation. Forward-looking information in this news release includes, but is not limited to, statements regarding the anticipated commencement, duration, scope and objectives of the marketing program; the nature and timing of the services to be provided by Nordcore; the advertising channels expected to be used; and the planned expenditure of the marketing budget. Forward-looking information is based on management’s current expectations, estimates, assumptions and projections as of the date of this news release, including assumptions that Nordcore will provide the services contemplated by the Agreement in accordance with its terms, that the planned advertising channels and third-party distributors will remain available on commercially reasonable terms, and that the marketing program and budget will proceed substantially as currently contemplated. 

Forward-looking information is inherently subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking information. These risks and uncertainties include, among others, changes in market conditions, advertising costs, platform policies or availability, campaign performance, audience engagement, the availability and performance of third-party service providers and advertising distributors, and changes in the timing, scope or budget of the Services. There can be no assurance that the marketing program will be completed as anticipated or will achieve its intended objectives. Additional risks and uncertainties applicable to the Company are described in the Company’s continuous disclosure filings available under its profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned not to place undue reliance on forward-looking information. The forward-looking information in this news release is provided as of the date hereof, and the Company undertakes no obligation to update or revise such information to reflect new events or circumstances, except as required by applicable law. 

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this news release.

New York, NY, Nov. 13, 2026 (GLOBE NEWSWIRE) — byNordic Acquisition Corporation (“BYNO” or the “Company”), a special purpose acquisition company, announced today that the Company has timely deposited into the Company’s trust account (the “Trust Account”), an aggregate of $8,850.20, in order to extend the period of time the Company has to complete a business combination for an additional one (1) month period, from November 12, 2026 to December 12, 2026 (the “Extension”). The Extension is the fourth of up to twelve (12) one-month extensions permitted under the August 7, 2026 amendment to the Company’s Amended and Restated Certificate of Incorporation that allows the Company’s board of directors, in its sole discretion and without another stockholder vote, to elect to extend the termination date by one additional month each time up until August 12, 2027, or the closing of the Company’s initial business combination.

About byNordic Acquisition Corporation

byNordic Acquisition Corporation, led by Chief Executive Officer Michael Hermansson, is a special purpose acquisition company formed with the purpose of entering into a business combination with one or more businesses. While the Company may pursue an initial business combination with a company in any sector or geography, it intends to focus its search on high technology growth companies based in the northern part of Europe.

Forward Looking Statements

This press release may include, and oral statements made from time to time by representatives of the Company may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the Securities and Exchange Commission. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

byNordic Acquisition Corporation Contact:

Michael Hermansson
+46 707 294100
ir@bynordic.se

–First Quarter Revenue Increased 27% Year-over-Year to $5.4 Million; Revenue Plus Interest Income of $5.9 Million*–

–Stock Locate Revenue of $3.0 Million–

–Revenue from Sources Other Than Commissions Rose to 68% of Total Revenue, from 45%–

–AtlasClearing Net Capital Increased to $15.2 Million, $14.9 Million in Excess of Requirements–

–Definitive Agreement to Acquire Ark Financial Services Signed and FINRA Continuing Membership Application Filed; Correspondent Network Expanded to Nine Signed Agreements–

–Earnings Conference Call Scheduled for Monday, November 16, 2026, at 8:30 AM ET–

TAMPA, Fla., Nov. 13, 2026 (GLOBE NEWSWIRE) — AtlasClear Holdings, Inc. (“AtlasClear” or the “Company”) (ATCH), a company building regulated financial infrastructure for smaller institutions, fintechs and advisors, today announced financial results for its fiscal first quarter ended September 30, 2026.

Fiscal First Quarter 2027 Financial Highlights

(Quarter Ended September 30, 2026)

• Revenue increased 27% year-over-year to $5.4 million, compared to $4.3 million in the prior-year quarter.
• Revenue plus interest income increased 24% to $5.9 million, compared to $4.7 million in the prior-year quarter.*
• Revenue from sources other than commissions represented approximately 68% of total revenue, compared to approximately 45% in the prior-year quarter, reflecting continued diversification of the revenue base.
• AtlasClearing’s net capital increased to $15.2 million at September 30, 2026, from $14.4 million at June 30, 2026, and was $14.9 million in excess of its minimum requirement, well above the $10 million excess net capital threshold the National Securities Clearing Corporation requires of firms that clear for introducing brokers.
• Stockholders’ equity was $20.7 million at September 30, 2026.
• Cash and cash equivalents totaled $9.4 million; total cash including segregated customer and PAB reserve cash totaled approximately $35.8 million.
• Net loss was $1.1 million, or $(0.01) per share, compared to a net loss of $0.4 million, or $(0.01) per share, in the prior-year quarter. Operating expenses included approximately $1.3 million in regulatory, legal and professional fees, driven by the planned Ark Financial Services and Commercial Bancorp transactions, and $0.6 million in non-cash stock-based compensation.

^{*This is a non-GAAP financial measure; see below for additional information.}

• Compensation, payroll taxes and benefits expense declined 13% year-over-year to $2.7 million, while revenue grew 27%.

Management Commentary

“We are building exactly the business we set out to build, and this quarter shows it,” said John Schaible, Executive Chairman of AtlasClear Holdings. “Revenue grew 27%, we built stock locate into our largest revenue line, and AtlasClearing’s net capital rose to $15.2 million. And we grew revenue while compensation costs fell 13%, which tells us that not every new dollar of revenue requires more people. We delivered that growth before our newly signed correspondents made any material contribution, which gives us confidence in the opportunity ahead. I know the recent trading suspension has been difficult for our shareholders, and we take that seriously. The Exchange’s action is about our share price. It is not about AtlasClearing’s regulatory capital, the Company’s financial condition or our operations. We intend to pursue the appeal process and seek to restore trading on the NYSE American, and we intend to seek to effect a reverse stock split as part of our plan to support the appeal and our continued listing. But the share price is not the business. The business is growing, the team is executing, and nothing about our foundation has changed.”

“Stock locate is the clearest proof of what this platform can do,” said Craig Ridenhour, President of AtlasClear Holdings and Chairman of AtlasClearing, Inc. “A year ago it did not exist, and this quarter it generated $3.0 million, more than any other part of our business. That is what happens when you add a new service to infrastructure that is already built and well capitalized. Now we are doing the same thing with correspondents. Every firm we bring through onboarding adds accounts and trading activity to an engine that already earns revenue across commissions, clearing, stock locate and interest, and we expect to support much of that growth with the platform and team already in place. My team is in that work every day, and none of it has slowed down.”

Operational and Strategic Highlights

During and following the quarter, AtlasClear continued executing on its strategy to build an integrated financial services platform combining clearing, capital markets and banking capabilities. Key developments included:

• In October 2026, signed a definitive business combination agreement to acquire Ark Financial Services, Inc., the parent of Dawson James Securities, Inc., and completed an initial 24.9% investment funded with $2.5 million in cash and a $2.5 million seller note, with no AtlasClear shares issued. Dawson James, an active underwriter and placement agent that already clears through AtlasClearing, reported 2025 revenue of $25.1 million and audited net income of $2.4 million. Because Ark’s principal serves on the Company’s board of directors, the transaction was reviewed and approved by AtlasClear’s independent directors.
• On November 12, 2026, the continuing membership application for Dawson James was filed with FINRA. FINRA approval is the principal regulatory condition to the acquisition of the remaining 75.1% of Ark, which also remains subject to stockholder approval to the extent required and other customary closing conditions. The remaining consideration will be paid solely in cash and AtlasClear common stock, with no warrants, preferred stock, convertible securities, discounts or price resets, and Ark stockholders receiving AtlasClear shares will be subject to a six-month lock-up.
• Expanded AtlasClearing’s correspondent network to nine signed correspondent broker-dealer agreements, four of which were signed since the start of fiscal 2027, with onboarding and conversion under way.
• Continued to scale stock locate operations, which generated $3.0 million in revenue in the quarter, close to half of the $6.8 million generated in all of fiscal 2026, its first year of operation.
• Remained committed to the planned acquisition of Commercial Bancorp of Wyoming, parent of Farmers State Bank, and expects to refile its regulatory applications at an appropriate time. The institutional digital asset opportunity announced in July 2026 remains subject to a non-binding letter of intent, due diligence and definitive agreements.

NYSE American Listing Update

On November 10, 2026, the Company announced that NYSE American had suspended trading in its common stock and commenced proceedings to delist the common stock, citing Section 1003(f)(v) of the NYSE American Company Guide based on the low selling price of the common stock. The Exchange’s determination is based solely on the low selling price of the common stock and does not relate to AtlasClearing’s regulatory capital compliance, the Company’s financial condition or the status of its correspondent clearing operations.

The Company intends to appeal the determination by requesting a hearing before a Listing Qualifications Panel of the Committee for Review of the Board of Directors of the Exchange, and currently intends to seek to effect a reverse stock split as part of its plan to support the appeal and its continued listing. During the appeal process, the common stock is being quoted on the OTC market under the symbol “ATCH.” AtlasClearing’s clearing operations continue in the ordinary course, and AtlasClearing remains compliant with its regulatory net capital requirements.

Fiscal First Quarter 2027 Financial Results

Revenue. Total revenue for the first quarter of fiscal 2027 was $5.4 million, an increase of 27% from $4.3 million in the prior-year quarter, driven by $3.0 million of stock locate fees, compared with none in the prior-year quarter. Revenue from sources other than commissions represented approximately 68% of total revenue, compared with approximately 45% in the prior-year quarter. Additional detail on revenue by line and on operating results will be available in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

Expenses and operating results. Total expenses were $7.9 million, compared with $5.1 million in the prior-year quarter. Compensation, payroll taxes and benefits declined 13% to $2.7 million from $3.1 million. Data processing and clearing costs increased to $1.9 million from $0.6 million, primarily reflecting costs associated with the stock locate business. Regulatory, professional and related expenses increased to $1.3 million from $0.3 million, driven by legal and professional advisory work on the planned Commercial Bancorp and Ark transactions. Non-cash stock-based compensation was $0.6 million, compared with $0.2 million. Loss from operations was $2.5 million, compared with $0.9 million in the prior-year quarter.

Other income and net loss. Total other income was $1.2 million, compared with $0.3 million in the prior-year quarter. The principal items included interest income of $0.5 million and non-cash gains of $0.7 million from the change in fair value of a secured convertible note, $0.3 million from the change in fair value of warrant liabilities and $0.2 million from the change in fair value of earnout liability, partially offset by interest expense of $0.4 million, a 72% decrease from $1.4 million in the prior-year quarter. After an income tax benefit of $0.2 million, net loss was $1.1 million, or $(0.01) per basic and diluted share, compared with a net loss of $0.4 million, or $(0.01) per share, in the prior-year quarter.

Balance Sheet and Capital

Total assets were $69.8 million at September 30, 2026. Stockholders’ equity was $20.7 million, compared to $21.1 million at June 30, 2026. AtlasClearing’s net capital increased $0.8 million during the quarter to $15.2 million. The change in cash and cash equivalents during the quarter primarily reflected net cash used in operating activities of $3.9 million, which included a $5.6 million increase in receivables from customers. AtlasClearing’s $10 million revolving line of credit with BMO Bank remained undrawn at September 30, 2026. Following the quarter, the Company paid $2.5 million in cash in connection with its initial investment in Ark, and it expects additional cash commitments of approximately $2.44 million payable at the closing of the Ark acquisition and $2.5 million under the seller note, which matures in January 2027 unless repaid earlier. Management’s base cash flow forecast indicates that projected operating cash flows and existing cash may not be sufficient to satisfy all anticipated obligations over the next twelve months. The Company is pursuing a committed PIPE financing, together with other available capital resources, to fund any potential shortfall, and based on these plans, management concluded that there is no substantial doubt about the Company’s ability to continue as a going concern.

Earnings Conference Call Information

Date: Monday, November 16, 2026
Time: 8:30 AM Eastern Time
Toll-Free (U.S. & Canada): 1-877-407-0752
U.S./International: 1-201-389-0912
Conference ID: 13763886
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1783251&tp_key=0b16d9eaed

Participants may also use the Call me™ link for instant telephone access to the event, available 15 minutes prior to the start time: https://callme.viavid.com/viavid/?callme=true&passcode=13756265&h=true&info=company&r=true&B=6

A telephone replay will be available approximately three hours after the conclusion of the call through Monday, November 30, 2026, at 11:59 PM ET, by dialing 1-844-512-2921 (toll-free U.S. & Canada) or 1-412-317-6671 (U.S./International) and entering access ID 13763886.

Non-GAAP Financial Measure

Revenue plus interest income is a supplemental measure that is not calculated in accordance with GAAP. AtlasClear presents interest income, which is earned on balances held at its broker-dealer subsidiary, in other income. Management believes that adding interest income to total revenues provides a useful view of the revenue generated by the Company’s operations. This measure should not be considered a substitute for total revenues determined in accordance with GAAP.

Reconciliation: First quarter fiscal 2027 GAAP total revenue of $5.4 million plus interest income of $0.5 million equals total revenue plus interest income of $5.9 million. First quarter fiscal 2026 GAAP total revenue of $4.3 million plus interest income of $0.5 million equals total revenue plus interest income of $4.7 million.

About AtlasClear Holdings, Inc.

AtlasClear Holdings, Inc. is building a technology-enabled financial services platform designed for trading, clearing, settlement, and banking for emerging financial institutions and fintechs. Through its wholly owned subsidiary AtlasClearing, Inc. (formerly Wilson-Davis & Co., Inc.), a full-service correspondent broker-dealer registered with the SEC and FINRA, its pending acquisition of Ark Financial Services, Inc., and its planned acquisition of Commercial Bancorp of Wyoming, AtlasClear Holdings seeks to deliver a vertically integrated suite of investment banking, brokerage, clearing, risk management, regulatory, and commercial banking solutions. For more information, follow us on LinkedIn or X and visit www.atlasclear.com.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that reflect AtlasClear Holdings’ current views with respect to, among other things, its future operations and financial performance. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will,” “would,” and similar expressions.

These statements include, but are not limited to, expectations regarding the onboarding and conversion of newly signed correspondent broker-dealers, the timing and amount of potential revenue contributions, expansion of the Company’s clearing, stock locate, stock loan, securities lending and margin businesses, operating efficiencies, anticipated benefits of strategic initiatives and proposed acquisitions, including the pending acquisition of Ark Financial Services, Inc., the planned acquisition of Commercial Bancorp of Wyoming and the proposed acquisition of an institutional digital asset business, the Company’s appeal of the NYSE American’s determination to delist its common stock and its ability to restore trading on the NYSE American, a potential reverse stock split, the quotation of the common stock on the OTC market, ability to raise required capital to pay its obligations, and future financial performance.

Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties, many of which are beyond the Company’s control. Actual results could differ materially from those anticipated due to factors including the outcome of the Company’s appeal of the NYSE American’s determination to delist its common stock, the risk that trading in the common stock does not resume on the NYSE American and that the common stock is delisted, the Company’s ability to effect a reverse stock split and to satisfy the NYSE American’s continued listing standards, the limited liquidity and potential volatility of the common stock while it is quoted on the OTC market, the effect of the trading suspension or any delisting on the market price of the common stock, the Company’s ability to raise capital, and its existing agreements and pending acquisitions, the risk that a definitive agreement for the proposed acquisition of an institutional digital asset business, which is the subject of a non-binding letter of intent (other than certain customary provisions), is not executed, the risk that proposed acquisitions are not completed on the anticipated terms or at all, including the risk that the Ark Financial Services transaction does not receive FINRA approval or stockholder approval or satisfy other closing conditions, the failure to obtain required regulatory approvals, including for the acquisition of Commercial Bancorp of Wyoming, difficulties integrating acquired businesses or realizing their anticipated benefits, dilution from the issuance of AtlasClear common stock, delays in onboarding correspondent broker-dealers, failure of correspondent relationships to generate anticipated revenue, termination of clearing agreements, changes in economic or political conditions or applicable laws, changes in trading activity and market conditions, regulatory developments, challenges in executing the Company’s business strategy, and other risks described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2026.

AtlasClear undertakes no obligation to update or revise forward-looking statements, except as required by law.

Company Contact
AtlasClear Holdings, Inc.
Email: AtlasClearIR@atlasclear.com

Investor Relations Contact
Jeff Ramson, CEO
PCG Advisory, Inc.
Email: jramson@pcgadvisory.com

Exclusively licensed Senlang’s CD7-Targeted lentiviral in vivo CAR-T platform following initial Phase 1 results with lead BCMA/GPRC5D candidate TPST-4903

Secured access to additional capital through an equity line of credit with Lincoln Park Capital Fund of up to $50.0 million and a private placement with gross proceeds of approximately $2.5 million

Strengthened Board of Directors with the appointments of Nancy Freda-Smith and John W. Frederick

BRISBANE, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced in vivo chimeric antigen receptor T-cell (“CAR-T”) product candidates to treat cancer and autoimmune disease, today reported financial results for the quarter ended September 30, 2026, and provided a business update.

“The third quarter marked a period of meaningful progress in the advancement of two next-generation in vivo CAR-T platforms with the potential to transform treatment across multiple diseases,” said Matt Angel, Ph.D., president and chief executive officer of Tempest. “We made important strides in expanding our pipeline and strengthening our position in the rapidly evolving in vivo CAR-T landscape through our strategic collaboration with Senlang by obtaining exclusive license rights to our clinical-stage BCMA/GPRC5D in vivo CAR-T candidate TPST-4903, while securing access to additional capital to support our development priorities. We also welcomed two accomplished independent directors to our Board, bringing valuable corporate governance and capital markets expertise as we navigate our next phase of growth. Together, these achievements reinforce our commitment to advancing our pipeline, executing on our strategic priorities and unlocking the broad therapeutic potential of in vivo CAR-T therapies for patients.”

Recent Highlights

• TPST-4903
  • Exercised option under agreement with Hebei Senlang Biotechnology Co., Ltd. to obtain an exclusive license to develop and commercialize Senlang’s CD7-targeted lentiviral vector platform and associated in vivo CAR-T candidates worldwide, excluding China.
  • The lead program, TPST-4903, is a BCMA/GPRC5D dual-targeting in vivo CAR-T candidate being evaluated in a Phase 1 dose-escalation study in patients with relapsed or refractory multiple myeloma (rrMM). The initial data demonstrating encouraging preliminary clinical responses are expected to be presented at an upcoming scientific conference.
• TPST-4003
  • Unveiled next-generation in vivo CAR-T pipeline, including lead product candidate TPST-4003, a dual-targeting CD19/BCMA in vivo CAR-T candidate that combines the Company’s proprietary CD7-targeted mRNA/LNP delivery with its clinically validated dual-target CAR architecture for broad B-cell lineage depletion and reset.
  • Executed a strategic partnership in July 2026 with Hebei Senlang Biotechnology to collaborate on the development of certain of Tempest’s proprietary in vivo CAR-T product candidates, including the Company’s next-generation CD7-targeted TPST-4003. An investigator-initiated trial in China evaluating TPST-4003 in approximately 10 patients with myasthenia gravis or multiple sclerosis is expected to begin in the fourth quarter of 2026.
• Corporate:
  • Completed a private placement in September 2026 of pre-funded warrants and Series C and D warrants for gross proceeds of approximately $2.5 million (approximately $1.8 million net of placement agent fees and offering expenses), excluding up to approximately $5.0 million of gross proceeds that may be received upon the cash exercise of the Series C and D warrants.
  • Entered into a purchase agreement with Lincoln Park Capital Fund, LLC on August 13, 2026 that gives Tempest the right, but not the obligation, to sell up to $25.0 million of its common stock, increasing to $50.0 million if the initial amount is sold, over a 24-month period that began September 1, 2026.Through September 30, 2026, Tempest sold 350,000 shares to Lincoln Park for gross proceeds of approximately $0.3 million.
  • Strengthened Board of Directors with the appointments of independent directors, Nancy Freda-Smith and John W. Frederick boosting corporate governance and capital markets expertise.

Financial Results

Third Quarter 2026

• Tempest ended the quarter with $0.9 million in cash and cash equivalents, compared to $7.7 million on December 31, 2025. The decrease was primarily due to cash used in operations, including one-time transaction-associated costs incurred prior to or upon closing of the Asset Acquisition in February 2026, offset by the net proceeds from the Company’s private placement of common stock and warrants in March 2026 of $1.7 million, the warrant inducement in May 2026 of $1.7 million, sales of common stock under the Lincoln Park equity line of credit of $0.3 million and the Company’s private placement in September 2026 of $1.8 million. The Company’s existing cash and cash equivalents are expected to fund its projected operating expense requirements for less than 12 months from the date the financial statements were available to be issued, and there is substantial doubt about the Company’s ability to continue as a going concern.
• Net loss and net loss per share for the quarter were $3.6 million and $0.21, respectively, compared to $3.5 million and $0.79, respectively, for the three months ended September 30, 2025.
• Research and development expenses for the quarter were $0.2 million compared to $0.6 million for the three months ended September 30, 2025. The $0.4 million decrease was primarily due to a decrease in costs incurred as a result of the portfolio re-prioritization after the Asset Acquisition in February 2026, offset by research and manufacturing costs related to the Company’s CAR-T product candidates.
• General and administrative expenses for the quarter were $2.6 million compared to $3.0 million for the same period in 2025. The $0.4 million decrease was primarily due to a decrease in one-time separation and other costs incurred in the third quarter of 2025, offset by other administrative expenses.
• Financing costs related to the Lincoln Park equity line of credit for the quarter were $0.8 million, consisting of $0.66 million for the fair value of the commitment shares issued to Lincoln Park and $0.15 million of issuance costs, net of a nominal gain on shares sold to Lincoln Park. There were no financing costs in the three months ended September 30, 2025.

Nine Months Ended September 30, 2026

• Cash used in operating activities for the nine months ended September 30, 2026 was $12.4 million.
• Net loss and net loss per share for the nine months ended September 30, 2026 were $36.6 million and $2.54, respectively, compared to $22.2 million and $5.71, respectively, for the same period in 2025.
• Research and development expenses for the nine months ended September 30, 2026 were $2.1 million, compared to $12.1 million for the same period in 2025. The $9.9 million decrease was primarily due to a decrease in costs incurred as a result of re-prioritizing efforts towards exploring strategic alternatives initiated in April 2025 and resulting in the Asset Acquisition completed in February 2026.
• General and administrative expenses for the nine months ended September 30, 2026 were $11.5 million, compared to $10.4 million for the same period in 2025. The $1.0 million increase was primarily due to one-time costs resulting from the Asset Acquisition completed in February 2026.
• Acquired in-process research and development expenses for the nine months ended September 30, 2026 were $22.2 million compared to nil for the nine months ended September 30, 2025. Costs incurred prior to or upon closing the Asset Acquisition in the prior three months ended March 31, 2026 were expensed as acquired in-process research and development.
• Financing costs related to the Lincoln Park equity line of credit for the nine months ended September 30, 2026 were $0.8 million, all of which were recognized in the third quarter of 2026. There were no financing costs in the nine months ended September 30, 2025.

About Tempest Therapeutics

Tempest is a clinical-stage biotechnology company developing a pipeline of advanced in vivo CAR-T therapies designed to treat cancer and autoimmune disease by resetting dysfunctional immunity. Tempest’s portfolio includes TPST-4903, a BCMA/GPRC5D dual-targeting in vivo CAR-T candidate being evaluated in a Phase 1 study for relapsed or refractory multiple myeloma (rrMM). The Company’s lead lipid nanoparticle (LNP)-based in vivo CAR-T candidate, TPST-4003 combines a clinically supported dual-targeting CD19/BCMA CAR structure with an advanced CD7-targeting delivery platform to support broad immune reset across multiple indications. The company’s additional preclinical programs leverage advanced payloads to create a modular in vivo CAR-T portfolio. Tempest envisions a world in which immune reset therapies bring safe, effective, and broadly accessible therapeutic options to patients in need. For additional information, visit Tempest’s website at https://www.tempesttx.com.

Forward-Looking Statements

This press release contains forward-looking statements, including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, concerning Tempest Therapeutics, Inc. These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest Therapeutics, as well as assumptions made by, and information currently available to, management of Tempest Therapeutics. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “could”, “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “goal”, “suggest”, “target” and other similar expressions. All statements that are not historical facts are forward-looking statements, including but not limited to, statements regarding: Tempest’s collaboration with Senlang and the advancement, development, design and potential benefits of TPST-4003; the planned investigator-initiated trial of TPST-4003, including the expected patient population, indications, number of patients, timing of first patient enrollment and dosing, expected assessments and anticipated timing and nature of initial and interim clinical data;  Tempest’s exclusive license to develop and commercialize Senlang’s CD7-targeted lentiviral vector platform and associated in vivo CAR-T candidates, and the anticipated benefits of that license; the advancement, development and potential benefits of TPST-4903, including the ongoing Phase 1 dose-escalation study; the expected presentation of initial data from that study at an upcoming scientific conference, and the nature and timing of that data; the potential applicability of Tempest’s platform and product candidates across autoimmune and oncology indications; Tempest’s business development and partnering plans, including in China; Tempest’s ability to access capital under its purchase agreement with Lincoln Park and the amount of proceeds it receives; and Tempest’s need for, and ability to obtain, additional capital to fund its planned programs and operations and continue as a going concern. All forward-looking statements in this press release are based on Tempest Therapeutics’ current expectations, estimates and projections about its industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to Tempest Therapeutics’ need for additional capital to fund its planned programs and operations and to continue to operate as a going concern; unexpected safety or efficacy data observed during preclinical or clinical trials; the possibility that results from prior clinical trials and preclinical studies may not necessarily be predictive of future results; past results may not be indicative of future results; clinical trial site activation or enrollment rates that are lower than expected; loss of key personnel; changes in expected or existing competition; changes in the regulatory environment; risks relating to volatility and uncertainty in the capital markets for biotechnology companies; dilution to stockholders from sales of common stock under the Lincoln Park purchase agreement and the exercise of outstanding warrants; Tempest’s ability to regain and maintain compliance with Nasdaq listing requirements; and unexpected litigation or other disputes. These and other factors that may cause actual results to differ from those expressed or implied are discussed in greater detail in the “Risk Factors” section of Tempest Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 30, 2026, in Tempest’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, expected to be filed with the SEC on November 13, 2026, and in other documents filed by Tempest Therapeutics from time to time with the SEC. Except as required by applicable law, Tempest Therapeutics undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest Therapeutics’ views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest Therapeutics.

TEMPEST THERAPEUTICS, INC.
Consolidated Balance Sheets
(in thousands)
	September 30, 2026				December 31, 2025
Assets
Current assets
Cash and cash equivalents	$	897			$	7,707
Prepaid expenses and other current assets		712				562
Total current assets		1,609				8,269
Property and equipment, net		429				605
Operating lease right-of-use assets		6,642				7,540
Other noncurrent assets		81				517
Total assets	$	8,761			$	16,931
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable	$	2,031			$	1,038
Accrued expenses		980				937
Current operating lease liabilities		1,336				1,192
Accrued compensation		322				147
Total current liabilities		4,669				3,314
Operating lease liabilities		5,922				6,949
Total liabilities		10,591				10,263
Stockholders’ equity
Common stock(1)		17				5
Additional paid-in capital(1)		277,098				240,031
Accumulated deficit		(278,945	)			(233,368	)
Total stockholders’ equity (deficit)		(1,830	)			6,668
Total liabilities and stockholders’ equity (deficit)	$	8,761			$	16,931

TEMPEST THERAPEUTICS, INC.
Consolidated Statements of Operations
(in thousands, except per share amounts)
	Three months ended				Three months ended				Nine months ended				Nine months ended
	September 30, 2026				September 30, 2025				September 30, 2026				September 30, 2025
Expenses:
Research and development	$	207			$	570			$	2,140			$	12,067
General and administrative		2,616				3,027				11,473				10,431
Acquired in-process research and development		–				–				22,180				–
Operating loss		(2,823	)			(3,597	)			(35,793	)			(22,498	)
Other income (expense), net:
Interest expense		–				–				–				(207	)
Interest and other income, net		–				86				30				464
Financing costs related to equity line of credit		(806	)			–				(806	)			–
Net loss	$	(3,629	)		$	(3,511	)		$	(36,569	)		$	(22,241	)
Net loss per share	$	(0.21	)		$	(0.79	)		$	(2.54	)		$	(5.71	)

Investor Contacts:

Alexandra Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

Manufacturing Work Addressing FDA CMC Information Requests Substantially Completed

NDA Resubmission Expected Between December 2026 and January 2027

KANSAS CITY, Kan., Nov. 13, 2026 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended September 30, 2026, and announced that it has substantially completed the manufacturing work required to address the U.S. Food and Drug Administration’s (FDA) chemistry, manufacturing and controls (CMC) information requests for CTx-1301. The Company expects to resubmit the new drug application (NDA) for CTx-1301 between December 2026 and January 2027.

“With the manufacturing work substantially complete, we are now finalizing the data and documentation needed to resubmit the NDA for CTx-1301, and we expect to do so by January 2027, potentially sooner,” stated Cingulate Chairman and CEO Shane J. Schaffer. “Importantly, the FDA’s Complete Response Letter did not raise any concerns about the clinical safety or efficacy of CTx-1301. We thank our shareholders for their patience and continued support as we work to bring this treatment to patients with ADHD.”

Regulatory Update: CTx-1301 NDA Resubmission Progress

On June 1, 2026, the FDA issued a Complete Response Letter (CRL) for the CTx-1301 (dexmethylphenidate HCl) NDA. The CRL identified specific requests for additional CMC information and did not identify any concerns regarding the clinical safety or efficacy of CTx-1301, the Company’s lead ADHD asset.

Since then, Cingulate and its contract development and manufacturing organization (CDMO), Bend Bioscience, have substantially completed the manufacturing work required to address the CMC requests in the CRL and are finalizing the supporting data and documentation for resubmission. As announced on November 9, 2026, the Company expects to resubmit the NDA between December 2026 and January 2027. After the FDA receives the resubmission, it is expected to classify it as a Class 1 or Class 2 resubmission, which carry review goals of two and six months, respectively.

Third Quarter Financial Results

Cash and Working Capital: As of September 30, 2026, Cingulate had approximately $23.2 million in cash and cash equivalents, compared to $11.0 million as of December 31, 2025. The increase was primarily driven by capital raised during the first nine months of 2026, including the close of a $12.0 million private placement in the first quarter and $22.5 million of capital raised on Cingulate’s At-the-Market Agreement with AGP and Purchase Agreement with Lincoln Park Capital, partially offset by $20.4 million in cash used for operations. As of September 30, 2026, Cingulate had approximately $18.8 million in working capital, an increase of $16.1 million as compared to December 31, 2025.

Under its current business plan, the Company believes its cash and cash equivalents will be sufficient to fund operations into mid-2027, including costs associated with seeking regulatory approval for CTx-1301, and continuing the build-out of commercial readiness capabilities.

R&D Expenses: Research and development expenses were $2.9 million for the three months ended September 30, 2026, an increase of 2.2% from $2.8 million for the three months ended September 30, 2025, driven primarily by higher drug manufacturing costs to address the CMC information requested in the FDA’s CRL, partially offset by lower clinical operations costs following the conclusion of clinical study activities in early 2025, the absence of regulatory costs incurred in the prior-year period in connection with preparing the CTx-1301 NDA, and lower personnel expenses. For the nine months ended September 30, 2026, R&D expenses were $6.6 million, a decrease of 15.3% from $7.8 million for the nine months ended September 30, 2025, driven primarily by lower clinical operations and regulatory costs, partially offset by increased manufacturing activities related to CTx-1301 following the CRL.

SG&A Expenses: Selling, general and administrative expenses (SG&A) were $4.6 million for the three months ended September 30, 2026, compared to $3.1 million for the three months ended September 30, 2025, an increase of 45.5%. For the nine months ended September 30, 2026, SG&A expenses were $14.2 million, compared to $6.6 million for the nine months ended September 30, 2025, an increase of 116.6%. The increases were driven primarily by the build-out of commercial readiness capabilities, including increased headcount and expanded market access, pricing, reimbursement and medical affairs activity conducted through Indegene, the Company’s commercialization partner.

Net Loss: Net loss was $7.7 million for the three months ended September 30, 2026, compared to $7.3 million for the three months ended September 30, 2025. For the nine months ended September 30, 2026, net loss was $22.9 million, compared to $16.2 million for the nine months ended September 30, 2025. The increases primarily reflect the higher SG&A expenses described above, partially offset in the third quarter by a smaller loss from the change in fair value of derivative and lower interest expense, and for the nine-month period by lower R&D expenses.

Cingulate Inc.
Consolidated Balance Sheet Data
		September 30,				December 31,
			2026				2025
Cash and cash equivalents		$	23,185,900			$	10,953,383
Total assets		$	28,150,677			$	15,073,263
Total liabilities		$	7,383,547			$	12,564,356
Working Capital		$	18,832,234			$	1,695,633
Accumulated deficit		$	(155,288,781	)		$	(132,375,031	)
Total stockholders’ equity		$	20,767,130			$	2,508,907

Cingulate Inc.
Consolidated Statements of Operations
		Three Months Ended September 30,								Nine Months Ended September 30,
			2026				2025				2026				2025
Operating expenses:
Research and development		$	2,910,660			$	2,848,544			$	6,581,803			$	7,772,109
Selling, general and administrative			4,580,358				3,147,291				14,247,412				6,579,735
Operating loss			(7,491,018	)			(5,995,835	)			(20,829,215	)			(14,351,844	)
Change in fair value of derivative			(69,323	)			(772,169	)			(1,235,366	)			(1,016,682	)
Interest and other income (expense), net			(171,056	)			(573,058	)			(849,169	)			(808,475	)
Loss before income taxes			(7,731,397	)			(7,341,062	)			(22,913,750	)			(16,177,001	)
Income tax benefit (expense)			–				–				–				–
Net loss			(7,731,397	)			(7,341,062	)			(22,913,750	)			(16,177,001	)

About Attention Deficit/Hyperactivity Disorder (ADHD)

ADHD is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood. The estimated market size of the US ADHD market is approximately 100 million annual prescriptions. The condition is marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. In the U.S., over 20 million patients have been diagnosed with ADHD. Among this group, 12 million are adults and over 8 million are under the age of 17. According to the CDC, just 53.6 percent of all children and teens with ADHD reported they were actively treating their symptoms with medication in 2022, with 65-90 percent demonstrating clinical ADHD symptoms that persist into adulthood. Current market trends demonstrate that adult ADHD prevalence is larger and growing faster than the child and adolescent segments combined.

About CTx-1301

CTx-1301 (dexmethylphenidate HCl) is a once-daily, multi-core tablet utilizing Cingulate’s proprietary Precision Timed Release™ (PTR™) platform to deliver three precisely timed releases of active medication across the day. This design aims to provide rapid onset of effect and entire active-day duration. CTx-1301 is being evaluated for the treatment of ADHD under the FDA’s 505(b)(2) pathway. In October 2025, the FDA accepted for review the NDA for CTx-1301 and assigned a PDUFA target action date of May 31, 2026. On June 1, 2026, the FDA issued a Complete Response Letter for the CTx-1301 NDA; the Company and its CDMO have since substantially completed the manufacturing work required to address the CMC requests, and the Company expects to resubmit the NDA between December 2026 and January 2026. There can be no assurance regarding the timing of any resubmission or whether approval will occur.

About Precision Timed Release™ (PTR™) Platform Technology

Cingulate is developing ADHD and anxiety disorder product candidates capable of achieving true once-daily dosing using Cingulate’s innovative PTR drug delivery platform technology. It incorporates a proprietary Erosion Barrier Layer (EBL) providing control of drug release at precise, pre-defined times with no release of drug prior to the intended release. The EBL technology is enrobed around a drug-containing core to give a tablet-in-tablet dose form. It is designed to erode at a controlled rate until eventually the drug is released from the core tablet. The EBL formulation, Oralogik™, is licensed from BDD Pharma. Cingulate intends to utilize its PTR technology to expand and augment its clinical-stage pipeline by identifying and developing additional product candidates in other therapeutic areas in addition to Anxiety and ADHD.

About Cingulate Inc.

Cingulate Inc. (NASDAQ: CING) is a biopharmaceutical company utilizing its proprietary PTR drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. For more information, visit Cingulate.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business, including statements with respect to our plans, assumptions, expectations, beliefs and objectives with respect to product development, clinical studies, clinical and regulatory timelines, the timing and outcome of any resubmission of the CTx-1301 NDA, market opportunity, competitive position, business strategies, potential growth opportunities, our expected cash runway, and anticipated capital needs and financing plans. These statements are generally identified by the use of such words as “may,” “could,” “should,” “would,” “believe,” “anticipate,” “forecast,” “estimate,” “expect,” “intend,” “plan,” “continue,” “outlook,” “will,” “potential” and similar statements of a future or forward-looking nature. Readers are cautioned that any forward-looking information provided by us or on our behalf is not a guarantee of future performance. Actual results may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our Annual Report on Form 10-K filed with the SEC on March 18, 2026 and our Quarterly Report on Form 10-Q for the period ended June 30, 2026, and our other filings with the SEC. All forward-looking statements speak only as of the date on which they are made, and we undertake no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

Investor & Media Relations:

Thomas Dalton

Vice President, Corporate and Government Relations, Cingulate

tdalton@cingulate.com 

(480) 529-5434

$0.533 per share dividend declared payable on December 10, 2026

HOUSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) — The Board of Directors of Westlake Corporation (NYSE: WLK) today declared a regular dividend distribution of $0.533 per share for the third quarter of 2026. This dividend will be payable on December 10, 2026 to stockholders of record on November 24, 2026.

Westlake announced its first dividend on November 11, 2004 and has successively been paying and increasing its dividend for the past 22 years.

The statements in this release that are not historical facts, including statements regarding future payment of dividend, are forward-looking statements. These forward-looking statements are subject to significant risks and uncertainties. For more detailed information about the factors that could cause actual results to differ materially, please refer to Westlake’s Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC in February 2026, and Westlake’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which was filed with the SEC in November 2026, respectively.

About Westlake

Celebrating 40 years of operations in 2026, Westlake is a global manufacturer and supplier of materials and innovative products that enhance life every day. Headquartered in Houston, with operations in Asia, Europe and North America, we provide the building blocks for vital solutions — from housing and construction, to packaging and healthcare, to automotive and consumer goods. For more information, visit the Company’s web site at www.westlake.com.

Contacts

Media Inquiries:
Westlake Corp.
Ben Ederington, 713-960-9111

or

Investor Inquiries:
Westlake Corp.
Jon Baksht, 713-960-9111